Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2016

Date: November 30, 2016
Pages: 509
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: A55886D8500EN
Leaflet:

Download PDF Leaflet

Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2016
Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Amyotrophic Lateral Sclerosis – Pipeline Review, H2 2016, provides an overview of the Amyotrophic Lateral Sclerosis (Central Nervous System) pipeline landscape.

Amyotrophic lateral sclerosis (ALS) is the most common degenerative disease of the motor neuron system. The disorder is named for its underlying pathophysiology, with amyotrophy referring to the atrophy of muscle fibers, which are denervated as their corresponding anterior horn cells degenerate. Lateral sclerosis refers to the changes seen in the lateral columns of the spinal cord as upper motor neuron (UMN) axons in these areas degenerate and are replaced by fibrous astrocytes (gliosis). Symptoms include difficulty breathing, difficulty swallowing, head drop due to weakness of the neck muscles, muscle cramps, speech problems, such as a slow or abnormal speech pattern (slurring of words), voice changes, hoarseness, weight loss.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Amyotrophic Lateral Sclerosis – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Amyotrophic Lateral Sclerosis (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Amyotrophic Lateral Sclerosis (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Amyotrophic Lateral Sclerosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 1, 2, 23, 12, 2, 74, 25 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 42 and 9 molecules, respectively.Amyotrophic Lateral Sclerosis.

Amyotrophic Lateral Sclerosis (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Amyotrophic Lateral Sclerosis (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Amyotrophic Lateral Sclerosis (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Amyotrophic Lateral Sclerosis (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Amyotrophic Lateral Sclerosis (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Amyotrophic Lateral Sclerosis (Central Nervous System)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Amyotrophic Lateral Sclerosis (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Amyotrophic Lateral Sclerosis (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Amyotrophic Lateral Sclerosis Overview
Therapeutics Development
Amyotrophic Lateral Sclerosis - Therapeutics under Development by Companies
Amyotrophic Lateral Sclerosis - Therapeutics under Investigation by Universities/Institutes
Amyotrophic Lateral Sclerosis - Pipeline Products Glance
Amyotrophic Lateral Sclerosis - Products under Development by Companies
Amyotrophic Lateral Sclerosis - Products under Investigation by Universities/Institutes
Amyotrophic Lateral Sclerosis - Companies Involved in Therapeutics Development
Amyotrophic Lateral Sclerosis - Therapeutics Assessment
Drug Profiles
Amyotrophic Lateral Sclerosis - Discontinued Products
Amyotrophic Lateral Sclerosis - Product Development Milestones
Appendix 488

LIST OF TABLES

Number of Products under Development for Amyotrophic Lateral Sclerosis, H2 2016
Number of Products under Development for Amyotrophic Lateral Sclerosis - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Development by Companies, H2 2016 (Contd..1)
Number of Products under Development by Companies, H2 2016 (Contd..2)
Number of Products under Development by Companies, H2 2016 (Contd..3)
Number of Products under Development by Companies, H2 2016 (Contd..4)
Number of Products under Development by Companies, H2 2016 (Contd..5)
Number of Products under Development by Companies, H2 2016 (Contd..6)
Number of Products under Development by Companies, H2 2016 (Contd..7)
Number of Products under Investigation by Universities/Institutes, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1)
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Comparative Analysis by Unknown Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Products under Development by Companies, H2 2016 (Contd..2)
Products under Development by Companies, H2 2016 (Contd..3)
Products under Development by Companies, H2 2016 (Contd..4)
Products under Development by Companies, H2 2016 (Contd..5)
Products under Development by Companies, H2 2016 (Contd..6)
Products under Development by Companies, H2 2016 (Contd..7)
Products under Development by Companies, H2 2016 (Contd..8)
Products under Investigation by Universities/Institutes, H2 2016
Products under Investigation by Universities/Institutes, H2 2016 (Contd..1)
Products under Investigation by Universities/Institutes, H2 2016 (Contd..2)
Amyotrophic Lateral Sclerosis - Pipeline by 2-BBB Medicines BV, H2 2016
Amyotrophic Lateral Sclerosis - Pipeline by AB Science SA, H2 2016
Amyotrophic Lateral Sclerosis - Pipeline by Aestus Therapeutics Inc, H2 2016
Amyotrophic Lateral Sclerosis - Pipeline by Anavex Life Sciences Corp, H2 2016
Amyotrophic Lateral Sclerosis - Pipeline by Angion Biomedica Corp, H2 2016
Amyotrophic Lateral Sclerosis - Pipeline by Apodemus AB, H2 2016
Amyotrophic Lateral Sclerosis - Pipeline by Apogenix GmbH, H2 2016
Amyotrophic Lateral Sclerosis - Pipeline by Apotex Inc, H2 2016
Amyotrophic Lateral Sclerosis - Pipeline by ArmaGen Inc, H2 2016
Amyotrophic Lateral Sclerosis - Pipeline by BioCrea GmbH, H2 2016
Amyotrophic Lateral Sclerosis - Pipeline by Biogen Inc, H2 2016
Amyotrophic Lateral Sclerosis - Pipeline by Biohaven Pharmaceutical Holding Company Limited, H2 2016
Amyotrophic Lateral Sclerosis - Pipeline by BioHealthonomics Inc, H2 2016
Amyotrophic Lateral Sclerosis - Pipeline by BrainStorm Cell Therapeutics Inc, H2 2016
Amyotrophic Lateral Sclerosis - Pipeline by Calico LLC, H2 2016
Amyotrophic Lateral Sclerosis - Pipeline by Catabasis Pharmaceuticals Inc, H2 2016
Amyotrophic Lateral Sclerosis - Pipeline by Cellceutix Corp, H2 2016
Amyotrophic Lateral Sclerosis - Pipeline by Chronos Therapeutics Ltd, H2 2016
Amyotrophic Lateral Sclerosis - Pipeline by ContraVir Pharmaceuticals Inc, H2 2016
Amyotrophic Lateral Sclerosis - Pipeline by Corcept Therapeutics Inc, H2 2016
Amyotrophic Lateral Sclerosis - Pipeline by Curatis Pharma GmbH, H2 2016
Amyotrophic Lateral Sclerosis - Pipeline by Cytokinetics Inc, H2 2016
Amyotrophic Lateral Sclerosis - Pipeline by Daval International Ltd, H2 2016
Amyotrophic Lateral Sclerosis - Pipeline by Edison Pharmaceuticals Inc, H2 2016
Amyotrophic Lateral Sclerosis - Pipeline by Eisai Co Ltd, H2 2016
Amyotrophic Lateral Sclerosis - Pipeline by Ensemble Therapeutics Corp, H2 2016
Amyotrophic Lateral Sclerosis - Pipeline by Evotec AG, H2 2016
Amyotrophic Lateral Sclerosis - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016
Amyotrophic Lateral Sclerosis - Pipeline by Flex Pharma, Inc., H2 2016
Amyotrophic Lateral Sclerosis - Pipeline by FPRT Bio Inc, H2 2016
Amyotrophic Lateral Sclerosis - Pipeline by Gemac, H2 2016
Amyotrophic Lateral Sclerosis - Pipeline by Genentech Inc, H2 2016
Amyotrophic Lateral Sclerosis - Pipeline by Genervon Biopharmaceuticals LLC, H2 2016
Amyotrophic Lateral Sclerosis - Pipeline by GeNeuro SA, H2 2016
Amyotrophic Lateral Sclerosis - Pipeline by GenKyoTex SA, H2 2016
Amyotrophic Lateral Sclerosis - Pipeline by Glialogix Inc, H2 2016
Amyotrophic Lateral Sclerosis - Pipeline by Grifols SA, H2 2016
Amyotrophic Lateral Sclerosis - Pipeline by Herantis Pharma Plc, H2 2016
Amyotrophic Lateral Sclerosis - Pipeline by ImStar Therapeutics Inc., H2 2016
Amyotrophic Lateral Sclerosis - Pipeline by InFlectis BioScience, H2 2016
Amyotrophic Lateral Sclerosis - Pipeline by Ionis Pharmaceuticals Inc, H2 2016
Amyotrophic Lateral Sclerosis - Pipeline by Italfarmaco SpA, H2 2016
Amyotrophic Lateral Sclerosis - Pipeline by Jeil Pharmaceutical Co Ltd, H2 2016
Amyotrophic Lateral Sclerosis - Pipeline by Kadimastem Ltd, H2 2016
Amyotrophic Lateral Sclerosis - Pipeline by Karyopharm Therapeutics Inc, H2 2016
Amyotrophic Lateral Sclerosis - Pipeline by KineMed Inc, H2 2016
Amyotrophic Lateral Sclerosis - Pipeline by Kringle Pharma Inc, H2 2016
Amyotrophic Lateral Sclerosis - Pipeline by Kyorin Pharmaceutical Co Ltd, H2 2016
Amyotrophic Lateral Sclerosis - Pipeline by Kyowa Hakko Kirin Co Ltd, H2 2016
Amyotrophic Lateral Sclerosis - Pipeline by Lascco SA, H2 2016
Amyotrophic Lateral Sclerosis - Pipeline by Lead Discovery Center GmbH, H2 2016
Amyotrophic Lateral Sclerosis - Pipeline by M's Science Corp, H2 2016
Amyotrophic Lateral Sclerosis - Pipeline by Maas Biolab, H2 2016
Amyotrophic Lateral Sclerosis - Pipeline by Mallinckrodt Plc, H2 2016
Amyotrophic Lateral Sclerosis - Pipeline by MedDay SA, H2 2016
Amyotrophic Lateral Sclerosis - Pipeline by MeiraGTx Limited, H2 2016
Amyotrophic Lateral Sclerosis - Pipeline by miCure Therapeutics Ltd., H2 2016
Amyotrophic Lateral Sclerosis - Pipeline by miRagen Therapeutics Inc, H2 2016
Amyotrophic Lateral Sclerosis - Pipeline by MitoDys Therapeutics Limited, H2 2016
Amyotrophic Lateral Sclerosis - Pipeline by Mitsubishi Tanabe Pharma Corp, H2 2016
Amyotrophic Lateral Sclerosis - Pipeline by Neuralstem Inc, H2 2016
Amyotrophic Lateral Sclerosis - Pipeline by Neuraltus Pharmaceuticals Inc, H2 2016
Amyotrophic Lateral Sclerosis - Pipeline by Neurimmune Holding AG, H2 2016
Amyotrophic Lateral Sclerosis - Pipeline by Neurotec Pharma SL, H2 2016
Amyotrophic Lateral Sclerosis - Pipeline by Neurotune AG, H2 2016
Amyotrophic Lateral Sclerosis - Pipeline by Orion Oyj, H2 2016
Amyotrophic Lateral Sclerosis - Pipeline by Orphazyme ApS, H2 2016
Amyotrophic Lateral Sclerosis - Pipeline by Pharnext SA, H2 2016
Amyotrophic Lateral Sclerosis - Pipeline by Plex Pharmaceuticals Inc, H2 2016
Amyotrophic Lateral Sclerosis - Pipeline by Prevacus Inc, H2 2016
Amyotrophic Lateral Sclerosis - Pipeline by Primary Peptides, Inc., H2 2016
Amyotrophic Lateral Sclerosis - Pipeline by ProMIS Neurosciences Inc, H2 2016
Amyotrophic Lateral Sclerosis - Pipeline by Q Therapeutics Inc, H2 2016
Amyotrophic Lateral Sclerosis - Pipeline by ReceptoPharm Inc, H2 2016
Amyotrophic Lateral Sclerosis - Pipeline by Regenesance BV, H2 2016
Amyotrophic Lateral Sclerosis - Pipeline by reMYND NV, H2 2016
Amyotrophic Lateral Sclerosis - Pipeline by Saneron CCEL Therapeutics Inc, H2 2016
Amyotrophic Lateral Sclerosis - Pipeline by SciFluor Life Sciences LLC, H2 2016
Amyotrophic Lateral Sclerosis - Pipeline by SK Biopharmaceuticals Co Ltd, H2 2016
Amyotrophic Lateral Sclerosis - Pipeline by Spherium Biomed SL, H2 2016
Amyotrophic Lateral Sclerosis - Pipeline by Symic Biomedical Inc, H2 2016
Amyotrophic Lateral Sclerosis - Pipeline by Teva Pharmaceutical Industries Ltd, H2 2016
Amyotrophic Lateral Sclerosis - Pipeline by Thera Neuropharma Inc, H2 2016
Amyotrophic Lateral Sclerosis - Pipeline by Treeway BV, H2 2016
Amyotrophic Lateral Sclerosis - Pipeline by Valeant Pharmaceuticals International Inc, H2 2016
Amyotrophic Lateral Sclerosis - Pipeline by ViroMed Co Ltd, H2 2016
Amyotrophic Lateral Sclerosis - Pipeline by VivaCell Biotechnology Espana SL, H2 2016
Amyotrophic Lateral Sclerosis - Pipeline by Voyager Therapeutics Inc, H2 2016
Amyotrophic Lateral Sclerosis - Pipeline by WAVE Life Sciences Ltd, H2 2016
Amyotrophic Lateral Sclerosis - Pipeline by Yooyoung Pharmaceutical Co Ltd, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Amyotrophic Lateral Sclerosis - Dormant Projects, H2 2016
Amyotrophic Lateral Sclerosis - Dormant Projects (Contd..1), H2 2016
Amyotrophic Lateral Sclerosis - Dormant Projects (Contd..2), H2 2016
Amyotrophic Lateral Sclerosis - Dormant Projects (Contd..3), H2 2016
Amyotrophic Lateral Sclerosis - Dormant Projects (Contd..4), H2 2016
Amyotrophic Lateral Sclerosis - Dormant Projects (Contd..5), H2 2016
Amyotrophic Lateral Sclerosis - Dormant Projects (Contd..6), H2 2016
Amyotrophic Lateral Sclerosis - Dormant Projects (Contd..7), H2 2016
Amyotrophic Lateral Sclerosis - Dormant Projects (Contd..8), H2 2016
Amyotrophic Lateral Sclerosis - Dormant Projects (Contd..9), H2 2016
Amyotrophic Lateral Sclerosis - Dormant Projects (Contd..10), H2 2016
Amyotrophic Lateral Sclerosis - Discontinued Products, H2 2016
Amyotrophic Lateral Sclerosis - Discontinued Products (Contd..1), H2 2016 495

LIST OF FIGURES

Number of Products under Development for Amyotrophic Lateral Sclerosis, H2 2016
Number of Products under Development for Amyotrophic Lateral Sclerosis - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Top 10 Routes of Administration, H2 2016
Number of Products by Stage and Top 10 Routes of Administration, H2 2016
Number of Products by Top 10 Molecule Types, H2 2016
Number of Products by Stage and Top 10 Molecule Types, H2 2016
Skip to top


Ask Your Question

Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: